Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...

Health care providers say that hesitation and outright resistance to vaccines have become disturbingly common even in ...

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case ... expected quarterly loss of $2.91 per share, compared to ...

Earnings: Discover insights into revenue shifts, cost reductions, 2027 product goals, RSV market strategies, and its broader ...

Moderna MRNA ... 2024 compared with $2.8 billion in the year-ago quarter. Per management, the decrease was primarily due to the earlier launch of the updated COVID-19 vaccine in the United States ...

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...

The UK has become the first country in the world to authorise an updated COVID-19 booster ... Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS ...

A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public. The cost per single dose varies but is typically between £75 and £99.

In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.